Article
An inherent T cell-activating mRNA delivery platform for <i>in vivo</i> CAR T generation
2025-11-20
Abstract excerpt
The clinical success of CAR T cell therapy has underscored the need for scalable, non-invasive strategies for in vivo T cell engineering. Although mRNA delivery offers a promising alternative, current lipid-based vectors lack intrinsic T cell tropism and often rely on antibody conjugation, complicating manufacturing and raising safety concerns. Here we present an inherent T cell-activating polymer–lipid nanoparti...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- d06895ce-a0f4-5c0c-9734-e97fea9b41ee
- DOI
- 10.1101/2025.11.19.688592
